assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
Published 22 hours ago • 57 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
3:17
pet imaging to predict treatment outcomes: follow-up from the echelon-2 trial
-
6:02
predicting treatment outcomes in patients with r/r chl with ctdna and pet
-
3:05
the benefits of pet in the prognosis and treatment of hl
-
2:15
the role of pet/ct in assessing early treatment response in patients with ndmm
-
1:52
petrea: evaluating pet-adapted maintenance therapy approaches for patients with follicular lymphoma
-
1:09
using mrd and pet/ct to assess responses post-asct in myeloma
-
1:54
navigating regulatory challenges in developing and approving therapies for rare lymphomas
-
1:01
pitfalls in the diagnosis of lymphoid malignancies: interpreting pet scans
-
1:13
utilizing pet/ct to improve staging in extranodal marginal zone lymphoma
-
2:11
genetic testing to risk stratify a patient with cll and aid in treatment decisions
-
1:28
use of machine learning to predict outcomes for patients with scd
-
6:21
prognostic significance of pet-ct status after first line immuno-chemotherapy for fl
-
2:02
phase ii animate trial investigating pet response-adapted treatment using nivolumab in r/r chl
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
2:41
cell avidity as a predictor of t-cell efficacy
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
2:06
introducing molecular diagnostics to improve leukemia care in developing countries